n i r jun 2017 -...

BULLETIN PENYELIDIKAN DAN

PEMBANGUNAN (R&D) FARMASI

NEGERI SELANGOR

JUN 2017

DITERBITKAN OLEH: JK R&D FARMASI SELANGOR

JAWATANKUASA R&D FARMASI SELANGOR 2017

SENARAI AHLI JAWATANKUASA

JK KECIL PENERBITAN

Sia Xin Ni Peg.Farmasi UF44 PKD Gombak

Noor Aini bt Zainal Abidin Peg.Farmasi UF44 Hosp Tanjung Karang

Hazwani bt Harith Peg.Farmasi UF44 Hosp Orang Asli Gombak

Sayeeda Zainab bt Hasnor Peg.Farmasi UF44 PKD Kuala Selangor

Nurul Syazwani bt Mohamad Peg.Farmasi UF44 PKD Kuala Langat

Muhammad Fahmi b Jamil Peg.Farmasi UF44 PKD Petaling

Hafizah bt Hassim Peg.Farmasi UF44 PKD Hulu Selangor

Norfaradila bt Mohamed Peg.Farmasi UF44 PKD Sepang

JK KECIL LATIHAN

Asmahani bt Ramelan Peg.Farmasi UF52 HTAR

Wong Su Li Peg.Farmasi UF44 PKD Klang

Jaya Mania Rao a/l Ramadoo Peg.Farmasi UF44 Hosp Kuala Kubu Bharu

Teh Wen Yan Peg.Farmasi UF44 HTAJ

Silambarasu a/l Karuppiah Peg.Farmasi UF44 PKD Sabak Bernam

Yah Xin Yun Pen.Pengarah Kanan Farmasi UF44 BPFJKNS

Cindy Fow Peg.Farmasi UF44 Hosp Banting

Dinesh a/l Widiadharan Peg.Farmasi UF44 Hosp Sg Buloh

JK KECIL SAINTIFIK

Aswani Yanti bt Baharuddin Peg.Farmasi UF52 Hosp Ampang

Dr. Wardati bt Mazlan Kepli Peg.Farmasi UF52 Hosp Serdang

Chong Pei Feng Peg.Farmasi UF48 Hosp Sg Buloh

Noorul Aimi bt Daud Peg.Farmasi UF48 Hosp Serdang

Josephine a/l Henry Basil Peg.Farmasi UF48 Hosp Shah Alam

Wan Nor Ashikin bt Wan Ibrahim Ketua Pen. Pengarah Kanan UF52 BPFJKNS

Ruwaida Nur bt Zainol Abidin Peg.Farmasi UF48 Hosp Serdang

Kong Su Shan Peg.Farmasi UF52 Hosp Ampang

Nur Kamalah bt Daud@Mahusain Peg.Farmasi UF52 PKD Hulu Langat

Mogana a/p Mathayena Peg.Farmasi UF44 Hosp Selayang

Puteri Juanita bt Zamri Peg.Farmasi UF48 Hosp Selayang

ISI KANDUNGAN

SENARAI AHLI

JAWATANKUASA

1

PENCAPAIAN KAJIAN R&D

FARMASI SELANGOR

JAN — DIS 2016

2

PENCAPAIAN KAJIAN R&D

FARMASI SELANGOR

JAN — JUN 2017

(PEMBENTANGAN DAN

PERSIDANGAN)

3-4

AKTIVITI JK R&D FARMASI

SELANGOR DAN

AKTIVITI R&D DI PTJ

JAN — JUN 2017

5

LATIHAN ANJURAN JK

R&D FARMASI SELANGOR

JAN — JUN 2017

6

PROGRAM AKAN DATANG 7

PENASIHAT PN. AKMALYATUN KAMAL BT KAMARUDDIN TIMBALAN PENGARAH

PENGERUSI PN. NORHALINA BT SULAIMAN Pegawai Farmasi UF52

PKD Klang

SETIAUSAHA I PN. SARAH DIYANA BT SHAFIE Pegawai Farmasi UF48

SETIAUSAHA II PN HANIATI BT HASAN Ketua Pen. Pengarah (A&P) UF52

BPF, Jabatan Kesihatan Negeri Selangor

PENCAPAIAN KAJIAN R&D FARMASI NEGERI SELANGOR

JAN — DIS 2016

JAWATANKUASA R&D FARMASI SELANGOR 2017

SENARAI AHLI JAWATANKUASA

Belum

dibentangkan, 6, 26%

Peringkat Negeri, 5,

22%

Peringkat

Kebangsaan, 12, 52%

Dibentangkan, 17,

74%

Bilangan Kajian Saintifik Selangor Yang Dibentangkan Di Persidangan 2016

Selesai, 23,

39%

Sedang

dijalankan, 36, 61%

Status Kajian Saintifik Selangor 2016

BULLETIN PENYELIDIKAN DAN PEMBANGUNAN (R&D)

FARMASI NEGERI SELANGOR

JUN 2017

( P I C )

C. L. Choong 1, H.S. Wong 2, F.Y. Lee 3, C.K. Lee 1, J.V. Kho 1, Y.X. Lai 1 , T.Vikneswaran1 .Does Introduction of Diltiazem to Reduce Tacrolimus Dosage Safe in Post-renal Transplant Recipients?

DOSE RESPONSE RELATIONSHIP BETWEEN DILTIAZEM AND TACROLIMUS IN

RENAL TRANSPLANT RECIPIENTS : A PHARMACOKINETIC STUDY

C. L. Choong 1, H.S. Wong 2, F.Y. Lee 3, C.K. Lee 1, J.V. Kho 1, Y.X. Lai 1 , T.Vikneswaran1 1 Pharmacy Department, 2 Nephrology Department, & 3 Clinical Research Centre, Selayang Hospital, Selangor, Malaysia INTRODUCTION: Inhibition of calcineurin inhibitors (CNI) metabolism with diltiazem will reduce the dose of tacrolimus required to achieve its therapeutic blood concentration in kidney transplant recipients (KTR). This cost-saving maneuver is practiced in several countries including Malaysia but actual impact of diltiazem on tacrolimus blood concentration, dose-response relationship and actu-al amount of cost-saving are not known. OBJECTIVE: To study the dose-response relationship between diltiazem and tacrolimus METHODS: This retrospective study was performed on all KTR from 1st January 2006 to 31st December 2015 (identified through the hospital kidney transplant database), who were prescribed with diltiazem to increase blood tacrolimus concentration. Demo-graphic data, tacrolimus and diltiazem dosage, blood tacrolimus trough level (TacC0) and other relevant clinical data were retrieved from hospital electronic medical record. Subjects under the age of 18, or with incomplete data, were excluded. RESULTS: A total of 75 KTR fulfilled study inclusion criteria and 59(79%) were deceased donor KTR. The mean age was 42.13±9.8years, and 42(56%) were male. The median time to introduction of diltiazem was 17±38days post-transplant. Dose of 1mg tacrolimus resulted in median TacC0 of 0.83±0.52ng/ml. With introduction of 90mg daily dose diltiazem, there was a further nett TacC0 increment by 1.39±1.31ng/mL/mg tacrolimus. Every further 90mg increase in diltiazem (total daily dose of 180mg, 270mg and 360mg diltiazem) results in near linear incremental median TacC0 of 1.65±2.58ng/mL/mg/day, 1.39±1.15ng/mL/mg/day and 1.24±0.94ng/mL/mg/day respectively. An average daily dose of 7mg tacrolimus is required to achieve a 6ng/ml drug level. Ad-dition of 90mg/day diltiazem reduced the required tacrolimus dose to 3mg/day, resulting in a saving of RM10369.65 per year at our center.

FIRST PRIZE WINNER-ORAL

SECOND PRIZE WINNER-ORAL

PENCAPAIAN KAJIAN R&D FARMASI SELANGOR JAN — JUN 2017

(PEMBENTANGAN DAN PERSIDANGAN)

(

)

SYABAS juga diucapkan kepada Pegawai-pegawai Farmasi dari Hospital/PKD di

Selangor yang telah berjaya menyertai Persidangan-persidangan Penyelidikan seperti berikut:

National Heart Association Malaysia NHAM Annual Scientific

Meeting 2017 conference (7-9/4/2017)

1. Y.C Chua, 1 P.F Chong 2. Statin Naive Patients In Acute Coronary Syn-

drome North Of Kuala Lumpur. 1 Department of Cardiology, UITM, 2 Depart-

ment of Pharmacy, Selayang Hospital.

2. Y.C Chua, 1 P.F Chong 2. ACS Medication Review In a CCU North Of Kuala

Lumpur. 1 Department of Cardiology, UITM, 2 Department of Pharmacy, Se-

layang Hospital.

3. M.K Wardati, M. Walters, C. Berry, J. Dawson. Cardiovascular events during

long term follow-up after cessation of dual antiplatelet therapy in patients

with acute coronary syndrome. Department of Pharmacy, Serdang Hospital.

4. M.K Wardati, M. Walters, C. Berry, J. Dawson. Identification of Metabolite

Changes in Plasma Following Ticagrelor Cessation in Acute Coronary Syn-

drome Patients Using Metabolomics. Department of Pharmacy, Serdang

Hospital.

5. Y.Y. Hoo, J.Y. Tai, A.M. Abdul Muizz, M.K. Wardati. Prior Antiplatelet Thera-

py and Clinical Outcome After Percutaneous Coronary Intervention. Depart-

ment of Pharmacy, Serdang Hospital.

1. Adnan, S1, Ratnam, S2, Naidu, P2,Md Mahir, H. Impact Of Antimicrobial

Stewardship On Antimicrobial Comsumption In Intensive Care Unit, Hospital

Sungai Buloh. Department of Pharmacy, Sungai Buloh Hospital.





MESYUARAT JK R&D LATIHANJK R&D

Mesyuarat JK R&D Bil 1/2017

(16 Februari 2017)

Mesyuarat JK Kecil Penerbitan, JK R&D

(24 Mei 2017)

Bengkel Manuscript Writing

(7-8 Mac 2017)

Aktiviti R&D: Pembentangan Proposal Kajian

Tarikh: 28 Februari 2017


Tarikh: 4 April 2017

Hospital

Kajang


Tajuk: ETA Lactam/ Carbapenem antibiotic plus

aminogkycoside vs monotherapy beta lactam/ car-

bapenem antibiotics therapy in hematology patient

with febrile neutropenia



Tajuk: Assessment of staff nurses’ knowledge on

storage of medication in ward


Aktiviti R&D: CME on “Role of intravenous glu-

tamine in hematology patients with chemother-

apy– induced oral mucositis

Hospital

Ampang

AKTIVITI JK R&D FARMASI SELANGOR

DAN AKTIVITI R&D DI PTJ JAN — JUN 2017

Tarikh: 7-8 Mac 2017

Tempat : Perpadanan Perpustakaan Awam Selangor (PPAS),

Seksyen 13 Shah Alam

Penceramah: Professor Low Wah Yun dari Universiti Malaya

Peserta : Semua AJK dan Liason Officer JK R&D

Objektif :

1. Mendedahkan dan meningkatkan kefahaman Pegawai Far-

masi mengenai penulisan manuskrip projek dan penerbi-

tan kajian.

2. Memberi kemahiran dalam menyusun, menganalis dan

mengemaskini pembentangan data keputusan mengikut for-

mat jurnal saintifik

3. Memahami proses penerbitan dan keperluan penerbitan se-

terusnya menghasilkan projek penyelidikan yang dapat

diterbitkan.

Bengkel Manuscript Writing

AKTIVITI JK R&D FARMASI SELANGOR

DAN AKTIVITI R&D DI PTJ JAN — JUN 2017 LATIHAN ANJURAN JK R&D FARMASI SELANGOR

JAN — JUN 2017

APHM International Conference & Exhibition 2017

Bengkel R&D 2017

Selangor Research Week 2017

National Conference for Clinical Research 2017

Tarikh: 25-27 Julai 2017

Tempat : KL Convention Center

Tarikh : 14-18 Ogos 2017

Tempat : Hospital Selayang

Deadline : 15 Jun 2017

Tarikh : 27-29 September 2017

Tempat : Putrajaya International Convention Center

Deadline : 15 Julai 2017

Tarikh : 12-14 September 2017

Tempat: BPF, JKNS

PROGRAM AKAN DATANG

n i r jun 2017 -...

Documents